On Apr. 19, 2021, CytoDyn announced it had submitted the manufacturing section (CMC) of the application for an Interim Order to Health Canada under a rolling review. This crucial part of the application documented the Company’s manufacturing (CMC) practices were in full compliance with GMP requirements.